T. Rowe Price reports 10.8% stake in BioLife Solutions (BLFS) common stock

Rhea-AI Filing Summary

T. Rowe Price Investment Management, Inc. filed an amended Schedule 13G reporting beneficial ownership of 5,180,824 shares of BioLife Solutions Inc. common stock, representing 10.8% of the class as of December 31, 2025. The firm has sole power to vote and dispose of all reported shares, with no shared voting or dispositive power.

The filer is classified as an investment adviser and states that the shares were acquired and are held in the ordinary course of business. It also certifies that the holdings are not intended to change or influence control of BioLife Solutions and expressly denies being the beneficial owner of the securities beyond what is required for reporting.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

BIOLIFE SOLUTIONS INC

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

09062W204

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 09062W204

1

Names of Reporting Persons

T. Rowe Price Investment Management, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

MARYLAND

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 5,180,824.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 5,180,824.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

5,180,824.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

10.8 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: BIOLIFE SOLUTIONS INC
(b)	Address of issuer's principal executive offices: 3303 MONTE VILLA PARKWAY, SUITE 310, BOTHELL, WA, 98021
Item 2.
(a)	Name of person filing: T. Rowe Price Investment Management, Inc.
(b)	Address or principal business office or, if none, residence: 1307 Point Street, Baltimore, MD 21231
(c)	Citizenship: Maryland
(d)	Title of class of securities: COMMON STOCK
(e)	CUSIP No.: 09062W204
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 5180824
(b)	Percent of class: 10.8 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 5180824
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 5180824
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. T. Rowe Price Investment Management, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Investment Management is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

T. Rowe Price Investment Management, Inc.

Signature:	Ellen York
Name/Title:	Vice President
Date:	01/08/2026

FAQ

What percentage of BioLife Solutions (BLFS) does T. Rowe Price Investment Management report owning?

T. Rowe Price Investment Management reports beneficial ownership of 10.8% of BioLife Solutions common stock as disclosed in the Schedule 13G/A.

How many BioLife Solutions (BLFS) shares does T. Rowe Price Investment Management beneficially own?

The filing reports beneficial ownership of 5,180,824 shares of BioLife Solutions common stock.

What voting and dispositive power does T. Rowe Price Investment Management have over BLFS shares?

The firm has sole voting power and sole dispositive power over all 5,180,824 reported shares, with no shared power reported.

On what date was the ownership position in BioLife Solutions effective for this Schedule 13G/A?

The date of the event requiring this statement is listed as December 31, 2025.

Does T. Rowe Price Investment Management intend to influence control of BioLife Solutions with this stake?

No. The certification states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of BioLife Solutions.

What type of reporting person is T. Rowe Price Investment Management in this BLFS filing?

T. Rowe Price Investment Management is identified as an investment adviser (IA) in the ownership report for BioLife Solutions common stock.

Who signed the Schedule 13G/A related to BioLife Solutions (BLFS) on behalf of T. Rowe Price Investment Management?

The statement is signed by Ellen York, Vice President, dated January 8, 2026.